Skyepharma

Skyepharma is a leading contract development and manufacturing organization (CDMO) specializing in innovative drug delivery and bioproduction solutions. With expertise in oral solid dosage forms and biotechnology, the company provides end-to-end services, from formulation development to commercial manufacturing. Headquartered in France, Skyepharma is committed to sustainability, innovation, and operational excellence. Its proprietary Skyehub-Bioproduction® model offers biotech companies a built-on-demand, fully equipped GMP facility, an established pharmaceutical quality system, and on-demand expert resources, enabling faster, more efficient drug development. Skyepharma’s capabilities extend to modified-release formulations, complex generics, and highly potent compounds, ensuring customized solutions to meet diverse industry needs. The company adheres to strict regulatory standards, delivering high-quality pharmaceutical and biopharmaceutical products that enhance patient care. With a strong focus on collaboration, flexibility, and quality, Skyepharma continues to expand its global presence, supporting partners in bringing innovative therapies to market efficiently and reliably.